Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains

Revvity reported Q1 2026 earnings with EPS of $1.06, beating estimates by $0.04, and revenue up 7% year-over-year. Shares rose 0.31% to $101.32 on May 8 on NYSE.

Revvity disclosed its first-quarter 2026 financial results, posting earnings per share of $1.06, which exceeded analyst expectations by $0.04. Revenue increased 7% year-over-year during the period, according to Ad-hoc-news.de as of May 2026. The stock advanced 0.31% to $101.32 on the NYSE on May 8 following the release.

Analyst sentiment on Revvity remains mixed with a consensus 'Hold' rating and an average price target of $107.73, per MarketBeat as of May 12, 2026. Recent SEC filings also show directors receiving restricted stock unit awards as part of compensation.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Revvity Inc.
• Sector/industry: Life sciences and diagnostics
• Headquarters/country: United States
• Core markets: North America, Europe, Asia
• Key revenue drivers: Discovery & innovation solutions, diagnostics
• Home exchange/listing venue: NYSE (RVTY)
• Trading currency: USD

Revvity: core business model

Revvity provides health science solutions, including reagents, instruments, and software for discovery and diagnostics. The company serves pharmaceutical, biotechnology, and academic customers globally, with a focus on precision medicine and drug development. Its portfolio spans life sciences tools and diagnostics for clinical and research applications.

Revvity operates through two main segments: Discovery & Innovation, which supports drug discovery and development, and Diagnostics, offering products for reproductive health, infectious disease testing, and enterprise analytics. This dual focus positions it in high-growth areas of the healthcare sector.

Main revenue and product drivers for Revvity

Revenue growth in Q1 2026 was driven by 7% year-over-year increase, reflecting demand in diagnostics and life sciences tools. Key products include mass spectrometry systems, genetic screening assays, and informatics software, which contribute significantly to top-line performance.

The company's emphasis on automation and AI-integrated solutions bolsters its revenue streams, particularly in North America where it generates a substantial portion of sales. US investors track Revvity for its exposure to biotech innovation and healthcare diagnostics markets.

Industry trends and competitive position

The life sciences tools sector benefits from rising R&D spending in biotech and pharma, with diagnostics growing amid personalized medicine advances. Revvity competes with firms like Thermo Fisher and Danaher, differentiating through specialized reagents and end-to-end workflows.

Recent earnings beats underscore Revvity's resilience in a competitive landscape, supported by recurring revenue from consumables and services.

Why Revvity matters for US investors

Listed on the NYSE, Revvity offers US investors direct access to innovations in drug discovery and diagnostics, sectors critical to the American healthcare economy. Its products support major US-based pharma trials and clinical labs.

Conclusion

Revvity's Q1 2026 results showed an earnings beat and revenue growth, with shares ticking higher post-release. Insider grants reflect ongoing board compensation practices. The company maintains a solid position in life sciences amid sector tailwinds, though analysts hold a cautious consensus view. Investors monitor upcoming catalysts like full-year guidance and product launches.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.